A Phase 1 interventional study of AZD0120 - Regimen 1 and AZD0120 - Regimen 2 in Multiple Sclerosis, sponsored by AstraZeneca. Recruiting at 20 sites in 5 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,192 studies in Multiple Sclerosis with a site in United States — 184 open to participants now, 259 under way, 23 of them phase 3. Multiple Sclerosis · United States.
Among the 1,192 studies in Multiple Sclerosis with a site in United States, this one is the 620th largest by planned enrollment of the 879 interventional ones that give a count, is one of 57 that started in 2025, is one of 105 in phase 1, reaches primary completion later than 193 of the 256 other live ones, and was the 1,132nd registered.
3,272 studies on the registry are indexed under Multiple Sclerosis; 664 are open to participants now.
Browse Multiple Sclerosis studies →184 of the 1,192 studies in Multiple Sclerosis with a site in United States are open now. Recruiting first, the newest first:
Sundance Biosciences, Inc. · Sites in United States
Ages 18–70
Genentech, Inc. · Sites in United States, Puerto Rico
Ages 18–65
The University of Texas Health Science Center, Houston · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 40–70
University of Texas at Austin · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 432 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 213 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,192 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 142 · Phase 2 191 · Phase 3 142 · Phase 4 82
First in 1976; this study’s year is marked. 57 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is below the median of 50 across 2,208 interventional studies indexed under Multiple Sclerosis.
Median enrollment 50 across the 879 interventional studies, 100 across the 302 observational. Of the 818 that completed or were terminated, 332 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
376 of 1,192 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 2 studies filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
78 of the studies in Multiple Sclerosis with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05134441Phase 3Immunic AGStudy to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | 2026-11 |
| NCT05877963Phase 3TG Therapeutics, Inc.Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab | 2027-01-21 |
| NCT06136728Phase 3MGH Institute of Health ProfessionsDalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis | 2027-05 |
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
| NCT07325292Phase 3SanofiNon-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis | 2027-07-15 |
Add all 78 to your calendar (.ics) → With an account.
Among the 1,192 studies in Multiple Sclerosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with relapsing and progessive Multiple Sclerosis.
This study will evaluate AZD0120 for safety, including DLTs and TEAEs, by the SRC for determination of the Recommended Phase 2 dose for RMS and PMS disease cohorts.
The criteria were revised on the registry on Nov 17, 2026. See what changed
Participants are eligible to be included in the study only if all of the following criteria apply:
Age
Age ≥ 18-years-old to ≤ 60-years-old at the time of consent
Type of Participant and Disease Characteristics
Adequate physiological function and reserve at screening
RMS Cohort Specific Inclusion Criteria
Evidence of active disease (clinical relapses and MRI activities within 2 years prior to screening) while on a high efficacy disease-modifying therapy for ≥ 6 months.
PMS Cohort Specific Inclusion Criteria
Exclusion Criteria
Participants are excluded from the study if any of the following criteria apply:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AZD0120 RMS
Biological: AZD0120 - Regimen 1 · Biological: AZD0120 - Regimen 2
AZD0120 PMS
Biological: AZD0120 - Regimen 1 · Biological: AZD0120 - Regimen 2
Regimen 1, infusion of AZD0120
Regimen 2, infusion of AZD0120
Evaluate the safety, and tolerability of AZD0120 in participants with MS (disease cohort 1: RMS; disease cohort 2: PMS)
Incidence and severity of Dose Limiting Toxicity (DLT) through Day 29 following AZD0120 administration.
Time frame: Day 1 to day 29
Evaluate the safety, and tolerability of AZD0120 in participants with MS (disease cohort 1: RMS; disease cohort 2: PMS)
Incidence and severity of Adverse Events (AE) over 104 weeks following AZD0120 administration.
Time frame: Day 1 to day 29, and over 104 weeks
Evaluate the safety, and tolerability of AZD0120 in participants with MS (disease cohort 1: RMS; disease cohort 2: PMS)
Incidence and severity of Serious Adverse Events (SAE) over 104 weeks following AZD0120 administration.
Time frame: Day 1 to day 29, and over 104 weeks
Evaluate the safety, and tolerability of AZD0120 in participants with MS (disease cohort 1: RMS; disease cohort 2: PMS)
Incidence and severity of Treatment Emergent Adverse Events (TEAE) over 104 weeks following AZD0120 administration.
Time frame: Day 1 to day 29, and over 104 weeks
Evaluate the optimum regimen with AZD0120 in MS participants to determine the RP2D in each disease cohort
Change from baseline in peripheral B-cell counts following AZD0120 administration
Time frame: Over 104 weeks
Evaluate the optimum regimen with AZD0120 in MS participants to determine the RP2D in each disease cohort
CK parameters in peripheral B-cell counts following AZD0120 administration
Time frame: Over 104 weeks
Evaluate the preliminary efficacy of AZD0120 in RMS and PMS
Annualized Relapse Rate (ARR) over 104 weeks (RMS cohort only)
Time frame: Over 104 weeks
Evaluate the preliminary efficacy of AZD0120 in RMS and PMS
Time to onset participants with CDP-12 over 104 weeks
Time frame: Over 104 weeks
Evaluate the preliminary efficacy of AZD0120 in RMS and PMS
Proportion of participants with CDP-12 over 104 weeks
Time frame: Over 104 weeks
Evaluate the preliminary efficacy of AZD0120 in RMS and PMS
Time to onset participants with CDP-24 over 104 weeks
Time frame: Over 104 weeks
Evaluate the preliminary efficacy of AZD0120 in RMS and PMS
Proportion of participants with CDP-24 over 104 weeks
Time frame: Over 104 weeks
Evaluate the preliminary efficacy of AZD0120 in RMS and PMS
Proportion of participants achieving CDI
Time frame: Over 104 weeks
Evaluate the preliminary efficacy of AZD0120 in RMS and PMS
Change from baseline in 9HPT (9-Hole Peg Test)
Time frame: Over 104 weeks
Evaluate the preliminary efficacy of AZD0120 in RMS and PMS
Change from baseline in T25FW (Timed 25-Foot Walk)
Time frame: Over 104 weeks
Evaluate the preliminary efficacy of AZD0120 in RMS and PMS
Change from baseline in EDSS (Expanded Disability Status Scale)
Time frame: Over 104 weeks
Evaluate the preliminary efficacy of AZD0120 in RMS and PMS
Change from baseline in SDMT (Symbol Digit Modalities Test)
Time frame: Over 104 weeks
Evaluate the preliminary efficacy of AZD0120 in RMS and PMS
Proportion of participants with NEDA-3 (No Evidence of Disease Activity)
Time frame: Over 104 weeks
Evaluate the preliminary efficacy of AZD0120 in RMS and PMS
Proportion of participants with PIRA (Progression Independent of Relapse Activity)
Time frame: Over 104 weeks
Evaluate the preliminary efficacy of AZD0120 in RMS and PMS
Change from screening in MRI parameters including: mean number of Gd+ T1 lesions over time
Time frame: Over 104 weeks
Evaluate the preliminary efficacy of AZD0120 in RMS and PMS
Change from screening in MRI parameters including: mean number of new or enlarging T2 hyperintense lesions
Time frame: Over 104 weeks
Evaluate the preliminary efficacy of AZD0120 in RMS and PMS
Change from screening in MRI parameters including brain volume
Time frame: Over 104 weeks
Evaluate the preliminary efficacy of AZD0120 in RMS and PMS
Change in MRI parameters including: mean number of Gd+ T1 lesions over time.
Time frame: Over 104 weeks
Evaluate the preliminary efficacy of AZD0120 in RMS and PMS
Change in MRI parameters including: mean number of new or enlarging T2 hyperintense lesions
Time frame: Over 104 weeks
Investigate the effects of AZD0120 on the function and quality of life of participants with MS
Change in SF-36v2 from baseline
Time frame: Over 104 weeks
Investigate the effects of AZD0120 on the function and quality of life of participants with MS
Change in Neuro-QoL-fatigue from baseline
Time frame: Over 104 weeks
Characterize the CK and PD of AZD0120 in participants with MS
Quantification of CAR transgene levels of AZD0120 in blood and CSF.
Time frame: Over 104 weeks
Characterize the CK and PD of AZD0120 in participants with MS
Cmax
Time frame: Over 104 weeks
Characterize the CK and PD of AZD0120 in participants with MS
AUC(0-28).
Time frame: Over 104 weeks
Characterize the CK and PD of AZD0120 in participants with MS
AUClast.
Time frame: Over 104 weeks
Characterize the CK and PD of AZD0120 in participants with MS
Clast.
Time frame: Over 104 weeks
Characterize the CK and PD of AZD0120 in participants with MS
Tmax.
Time frame: Over 104 weeks
Characterize the CK and PD of AZD0120 in participants with MS
Tlast.
Time frame: Over 104 weeks
Characterize the CK and PD of AZD0120 in participants with MS
B-cell counts
Time frame: Over 104 weeks
To monitor the incidence of vector-derived RCL
Proportion of participants with detectable RCL at pre-specified post infusion timepoints
Time frame: Over 104 weeks
To assess the immunogenicity of AZD0120 in participants.
Proportion of participants who develop anti- AZD0120 antibodies
Time frame: over 104 weeks
To assess the immunogenicity of AZD0120 in participants.
Time to development of anti-AZD0120 antibodies
Time frame: over 104 weeks
To assess the immunogenicity of AZD0120 in participants.
Changes in anti-AZD0120 antibody titers over 104 weeks
Time frame: over 104 weeks
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Dec 2028, 36 months after the start.
Of 39 industry-sponsored phase 1 interventional studies under Multiple Sclerosis, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 32. This study's planned 36 months is above that.
Counting every sponsor, half of 92 studies reached it within 30 months; a quarter within 9 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F